Agent Affecting Bone Metabolism
Click the image for product info
Oledron 4mg / 5ml
| Composition: | Zoledronic acid anhydrous 4mg. |
| Indication: | Prevention of skeletal related events pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced (hypercalcaemia) in patients with advanced malignancies involving bone. Treatment of hypercalcemia of malignancy (HCM). |
| Packing: | 5ml vial |
| Composition: | Pamidronate Disodium 3mg/ml. |
| Indication: | Treatment of conditions associated with increased osteoclast activity: Predominantly lytic bone metastases and multiple myeloma; tumour-induced hypercalcaemia; Paget’s disease of bone. |
| Packing: | 1 x 10ml vial |
